Mechanisms of disease

Inflammatory mediators and cancer prevention

Jason R. Mann, Michael G. Backlund, Raymond N. DuBois

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Discovery of molecular pathways critical to carcinogenesis is revolutionizing the treatment and prevention of cancer. Traditional chemotherapeutic approaches usually cause'global'cytotoxicity to both normal and carcinoma cells. Over the past decade, however, investigators have developed compounds that inhibit tumor formation more selectively by targeting specific signaling pathways, including those involving the epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX2). COX2-derived bioactive lipids, including prostaglandin E2, are potent inflammatory mediators that promote tumor growth and metastasis through stimulation of cell proliferation, invasion, and angiogenesis. Recent work has demonstrated significant crosstalk between the COX2 and EGFR pathways, while prechnical data demonstrates a synergistic effect when both pathways are targeted simultaneously. Combination therapy, a common strategy in cancer treatment, is likely to improve outcomes in cancer prevention as well. Ongoing clinical trials designed to assess whether low doses of COX2 and EGFR inhibitors used in combination could prove more effective and result in reduced toxicity than either agent alone may provide new options for cancer prevention and treatment. We discuss advances in cancer prevention by focusing on mechanisms by which bioactive lipids contribute to tumor formation. While cancer chemoprevention is a relatively young field, we argue that this approach to malignant disease bears significant potential.

Original languageEnglish (US)
Pages (from-to)202-210
Number of pages9
JournalNature Clinical Practice Oncology
Volume2
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Neoplasms
Epidermal Growth Factor Receptor
Lipids
Critical Pathways
Chemoprevention
Therapeutics
Dinoprostone
Carcinogenesis
Research Personnel
Cell Proliferation
Clinical Trials
Neoplasm Metastasis
Carcinoma
Growth

Keywords

  • 15-PGDH
  • Cancer
  • Chemoprevention
  • Cyclooxygenase 2
  • Prostaglandins

ASJC Scopus subject areas

  • Oncology

Cite this

Mechanisms of disease : Inflammatory mediators and cancer prevention. / Mann, Jason R.; Backlund, Michael G.; DuBois, Raymond N.

In: Nature Clinical Practice Oncology, Vol. 2, No. 4, 04.2005, p. 202-210.

Research output: Contribution to journalArticle

Mann, Jason R. ; Backlund, Michael G. ; DuBois, Raymond N. / Mechanisms of disease : Inflammatory mediators and cancer prevention. In: Nature Clinical Practice Oncology. 2005 ; Vol. 2, No. 4. pp. 202-210.
@article{4b7f674f756c4ddca73d13446d2b2d97,
title = "Mechanisms of disease: Inflammatory mediators and cancer prevention",
abstract = "Discovery of molecular pathways critical to carcinogenesis is revolutionizing the treatment and prevention of cancer. Traditional chemotherapeutic approaches usually cause'global'cytotoxicity to both normal and carcinoma cells. Over the past decade, however, investigators have developed compounds that inhibit tumor formation more selectively by targeting specific signaling pathways, including those involving the epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX2). COX2-derived bioactive lipids, including prostaglandin E2, are potent inflammatory mediators that promote tumor growth and metastasis through stimulation of cell proliferation, invasion, and angiogenesis. Recent work has demonstrated significant crosstalk between the COX2 and EGFR pathways, while prechnical data demonstrates a synergistic effect when both pathways are targeted simultaneously. Combination therapy, a common strategy in cancer treatment, is likely to improve outcomes in cancer prevention as well. Ongoing clinical trials designed to assess whether low doses of COX2 and EGFR inhibitors used in combination could prove more effective and result in reduced toxicity than either agent alone may provide new options for cancer prevention and treatment. We discuss advances in cancer prevention by focusing on mechanisms by which bioactive lipids contribute to tumor formation. While cancer chemoprevention is a relatively young field, we argue that this approach to malignant disease bears significant potential.",
keywords = "15-PGDH, Cancer, Chemoprevention, Cyclooxygenase 2, Prostaglandins",
author = "Mann, {Jason R.} and Backlund, {Michael G.} and DuBois, {Raymond N.}",
year = "2005",
month = "4",
doi = "10.1038/ncponc0140",
language = "English (US)",
volume = "2",
pages = "202--210",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Mechanisms of disease

T2 - Inflammatory mediators and cancer prevention

AU - Mann, Jason R.

AU - Backlund, Michael G.

AU - DuBois, Raymond N.

PY - 2005/4

Y1 - 2005/4

N2 - Discovery of molecular pathways critical to carcinogenesis is revolutionizing the treatment and prevention of cancer. Traditional chemotherapeutic approaches usually cause'global'cytotoxicity to both normal and carcinoma cells. Over the past decade, however, investigators have developed compounds that inhibit tumor formation more selectively by targeting specific signaling pathways, including those involving the epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX2). COX2-derived bioactive lipids, including prostaglandin E2, are potent inflammatory mediators that promote tumor growth and metastasis through stimulation of cell proliferation, invasion, and angiogenesis. Recent work has demonstrated significant crosstalk between the COX2 and EGFR pathways, while prechnical data demonstrates a synergistic effect when both pathways are targeted simultaneously. Combination therapy, a common strategy in cancer treatment, is likely to improve outcomes in cancer prevention as well. Ongoing clinical trials designed to assess whether low doses of COX2 and EGFR inhibitors used in combination could prove more effective and result in reduced toxicity than either agent alone may provide new options for cancer prevention and treatment. We discuss advances in cancer prevention by focusing on mechanisms by which bioactive lipids contribute to tumor formation. While cancer chemoprevention is a relatively young field, we argue that this approach to malignant disease bears significant potential.

AB - Discovery of molecular pathways critical to carcinogenesis is revolutionizing the treatment and prevention of cancer. Traditional chemotherapeutic approaches usually cause'global'cytotoxicity to both normal and carcinoma cells. Over the past decade, however, investigators have developed compounds that inhibit tumor formation more selectively by targeting specific signaling pathways, including those involving the epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX2). COX2-derived bioactive lipids, including prostaglandin E2, are potent inflammatory mediators that promote tumor growth and metastasis through stimulation of cell proliferation, invasion, and angiogenesis. Recent work has demonstrated significant crosstalk between the COX2 and EGFR pathways, while prechnical data demonstrates a synergistic effect when both pathways are targeted simultaneously. Combination therapy, a common strategy in cancer treatment, is likely to improve outcomes in cancer prevention as well. Ongoing clinical trials designed to assess whether low doses of COX2 and EGFR inhibitors used in combination could prove more effective and result in reduced toxicity than either agent alone may provide new options for cancer prevention and treatment. We discuss advances in cancer prevention by focusing on mechanisms by which bioactive lipids contribute to tumor formation. While cancer chemoprevention is a relatively young field, we argue that this approach to malignant disease bears significant potential.

KW - 15-PGDH

KW - Cancer

KW - Chemoprevention

KW - Cyclooxygenase 2

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=20444463535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444463535&partnerID=8YFLogxK

U2 - 10.1038/ncponc0140

DO - 10.1038/ncponc0140

M3 - Article

VL - 2

SP - 202

EP - 210

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 4

ER -